Lilly Shares Rise on Strong Foundayo Phase 3 Diabetes Trial Results
Eli Lilly's stock gains after positive Phase 3 data for its oral diabetes drug Foundayo boosts market confidence in the treatment's outlook. Eli Lilly (LLY) shares rose 2.16% to $1,155.84 on Monday, extending a weekly gain to 4.62%. The increase follows the release of robu